Literature DB >> 16316964

Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men.

Tobias Pischon1, Cynthia J Girman, Frank M Sacks, Nader Rifai, Meir J Stampfer, Eric B Rimm.   

Abstract

BACKGROUND: Apolipoprotein B (apoB) plasma levels reflect the concentration of proatherogenic lipoproteins very low-density lipoprotein and low-density lipoprotein (LDL), whereas non-high-density lipoprotein cholesterol (non-HDL-C) levels reflect the concentration of cholesterol transported by these particles. METHODS AND
RESULTS: The aim of our study was to compare apoB, non-HDL-C, LDL cholesterol (LDL-C), and other lipid markers as predictors of coronary heart disease (CHD) in a nested case-control study among 18 225 participants in the Health Professionals Follow-up Study. Among men who were free of diagnosed cardiovascular disease at the time of blood collection, 266 had nonfatal myocardial infarction or fatal CHD during 6 years of follow-up. Through the use of risk set sampling, control subjects were selected at a 2:1 ratio and matched with regard to age, date of blood collection, and smoking status. After adjustment for matching factors, the relative risk of CHD in the highest quintile compared with the lowest quintile was 2.76 (95% confidence interval [CI], 1.66 to 4.58) for non-HDL-C, 3.01 (95% CI, 1.81 to 5.00) for apoB, 1.81 (95% CI, 1.12 to 2.93) for LDL-C, 0.31 (95% CI, 0.18 to 0.52) for HDL-C, 2.41 (95% CI, 1.43 to 4.07) for triglycerides (all P trend <0.001), and 1.42 (95% CI, 0.86 to 2.32, P trend =0.19) for lipoprotein(a). When non-HDL-C and LDL-C were mutually adjusted, only non-HDL-C was predictive of CHD. When non-HDL-C and apoB were mutually adjusted, only apoB was predictive; the relative risk was 4.18 (95% CI, 1.30 to 13.49; P trend =0.02) for apoB compared with 0.70 (95% CI, 0.21 to 2.27; P trend =0.72) for non-HDL-C. Triglycerides added significant information to non-HDL-C but not to apoB for CHD risk prediction.
CONCLUSIONS: Although non-HDL-C and apoB were both strong predictors of CHD in this male cohort, more so than LDL-C, the findings support the concept that the plasma concentration of atherogenic lipoprotein particles measured by apoB is more predictive in development of CHD than the cholesterol carried by these particles, measured by non-HDL-C.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16316964     DOI: 10.1161/CIRCULATIONAHA.104.532499

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  114 in total

1.  Clinical applications of advanced lipoprotein testing in diabetes mellitus.

Authors:  Danyaal S Moin; Anand Rohatgi
Journal:  Clin Lipidol       Date:  2011-08-01

2.  Association of high-density lipoprotein cholesterol with incident cardiovascular events in women, by low-density lipoprotein cholesterol and apolipoprotein B100 levels: a cohort study.

Authors:  Samia Mora; Julie E Buring; Paul M Ridker; Yadong Cui
Journal:  Ann Intern Med       Date:  2011-12-06       Impact factor: 25.391

3.  The triglyceride:high-density lipoprotein-cholesterol ratio and steno-occlusive disease in the intracranial arteries.

Authors:  Kyusik Kang; Kwangsub Lee; Sung-Hoon Chung
Journal:  J Thromb Thrombolysis       Date:  2011-07       Impact factor: 2.300

4.  Association of apolipoprotein A1 and B with kidney function and chronic kidney disease in two multiethnic population samples.

Authors:  Oemer-Necmi Goek; Anna Köttgen; Ron C Hoogeveen; Christie M Ballantyne; Josef Coresh; Brad C Astor
Journal:  Nephrol Dial Transplant       Date:  2012-01-28       Impact factor: 5.992

5.  Dietary interventions that lower lipoproteins containing apolipoprotein C-III are more effective in whites than in blacks: results of the OmniHeart trial.

Authors:  Jeremy D Furtado; Hannia Campos; Anne E Sumner; Lawrence J Appel; Vincent J Carey; Frank M Sacks
Journal:  Am J Clin Nutr       Date:  2010-09-08       Impact factor: 7.045

6.  Using apolipoprotein B to manage dyslipidemic patients: time for a change?

Authors:  Charles R Harper; Terry A Jacobson
Journal:  Mayo Clin Proc       Date:  2010-05       Impact factor: 7.616

Review 7.  Lipid parameters for measuring risk of cardiovascular disease.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; John J P Kastelein
Journal:  Nat Rev Cardiol       Date:  2011-02-01       Impact factor: 32.419

Review 8.  Low-density lipoprotein and apolipoprotein B: clinical use in patients with coronary heart disease.

Authors:  William C Cromwell; Thomas A Barringer
Journal:  Curr Cardiol Rep       Date:  2009-11       Impact factor: 2.931

9.  Reducing vascular events risk in patients with dyslipidaemia: an update for clinicians.

Authors:  Michel P Hermans; Jean-Charles Fruchart
Journal:  Ther Adv Chronic Dis       Date:  2011-09       Impact factor: 5.091

10.  Lipid and lipoprotein profiles in youth with and without type 1 diabetes: the SEARCH for Diabetes in Youth case-control study.

Authors:  John Guy; Lorraine Ogden; R Paul Wadwa; Richard F Hamman; Elizabeth J Mayer-Davis; Angela D Liese; Ralph D'Agostino; Santica Marcovina; Dana Dabelea
Journal:  Diabetes Care       Date:  2008-12-17       Impact factor: 19.112

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.